"CURSOR" conference: new solutions in therapeutic approach to patients with heart failure

• Alexander S. Ametov
• Olga P. P'yanykh

Abstract

Long-term diabetes is often complicated by heart failure and chronic kidney disease. According to the Russian National Register, 26% of patients with type 2 diabetes died from chronic heart failure in 2020. Cardiovascular disease in absence of diabetes is also associated with a high risk of unfavorable prognosis.

Based on the results of the EMPEROR-Reduced study, dedicated to treatment of patients with heart failure with reduced ejection fraction (HFrEF), empagliflozin was included in the ESC (European Society of Cardiology) Clinical Practice Guidelines for the treatment of heart failure as the basis of the quad therapy for patients with HFrEF to reduce risk of death and hospitalization due to HF (regardless of the presence or absence of type 2 diabetes mellitus). This paper presents an overview of the "CURSOR" conference results, the purpose of which was to discuss and evaluate new clinical guidelines for 2021 in terms of implementation into real clinical practice, as well as to search for new solutions in treatment of heart failure.

Keywords:heart failure with reduced ejection fraction, type 2 diabetes mellitus, empagliflozin, CURSOR

REFERENCES

1. World Health Organization https://www.who.int/ru/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (date of access: 19.11.2021).

2. Morrish N.J., Wang S.L., Stevens L.K., Fuller J.H., Keen H. Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001; 44 (Suppl 2): 14-21. DOI: https://doi.org/10.1007/PL00002934

3. Dedov I.I., Shestakova M.V. National register of diabetes mellitus. (in Russian)

4. Birkeland K.I., J0rgensen M.E., Carstensen B., Persson F., Gul-seth H.L., Thuresson M., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017; 5 (9): 709-17. DOI: https://doi.org/10.1016/S2213-8587(17)30258-9

5. Kosiborod M., Lam C.S.P., Kohsaka S., Kim D.J., Karasik A., Shaw J., et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018; 71 (23): 2628-39. DOI: https://doi.org/10.1016/j.jacc.2018.03.009

6. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373: 2117-8. DOI: https://doi.org/10.1056/NEJMoa1504720

7. Packer M., Anker S.D., Butler J., et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020; 383 (15): 1413-24. DOI: https://doi.org/10.1056/NEJMoa2022190

8. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021; 42 (36): 3599-726. DOI: https://doi.org/10.1093/eurheartj/ehab368

9. Schernthaner G., Shehadeh N., Ametov A., et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology. 2020; 19: 185.

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)